ZNF37BP

Across TCGA pan-cancer cohorts, ZNF37BP RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated ZNF37BP data layer compared with 4 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF37BP RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF37BP expression acts as an unfavorable survival marker, although some lineages such as PAAD and HNSC show a favorable association.

LIHC, ACC, and PAAD are the cancer types where ZNF37BP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.694	0.868	<.001	72	view →
ACC	DFS	Median	All	0.376	0.778	<.001	72	view →
PAAD	OS	Median	All	0.605	0.399	.002	48	view →
KIRC	DFS	Quartile	II,III,IV	0.375	0.678	.005	43	view →
KICH	DFS	Tertile	II,III,IV	0.504	0.894	.009	32	view →
HNSC	DFS	Median	IV	0.710	0.576	.004	24	view →
GBM	DFS	Quartile	All	0.543	0.219	.002	22	view →
READ	OS	Median	II,III,IV	1.000	0.848	.008	22	view →
LUSC	DFS	Quartile	III,IV	0.299	0.951	.006	16	view →
SKCM	OS	Quartile	III,IV	0.578	0.211	.002	15	view →
KIRP	DFS	Tertile	All	0.608	0.772	.005	14	view →
UCS	OS	Tertile	IV	1.000	0.374	.049	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

ZNF37BP–LIHC (OS)

Open the LIHC breakdown →